Opus Genetics (IRD) Non-Current Receivables (2010 - 2011)
Opus Genetics (IRD) reported Non-Current Receivables of $4671.0 for Q2 2011, down 75.0% on a QoQ basis from $18682.0 in Q4 2010.
Opus Genetics (IRD) has 2 years of Non-Current Receivables data on file, last reported at $4671.0 in Q2 2011.
- Quarterly Non-Current Receivables changed N/A year-over-year to $4671.0 in Q2 2011, while the trailing twelve-month figure through Jun 2011 was $4671.0 (changed N/A YoY) and the FY2010 annual result came in at $18682.0, changed N/A from the prior year.
- Non-Current Receivables slipped to $4671.0 in Q2 2011 per IRD's latest filing, from $18682.0 in the prior quarter.
- Across five years, Non-Current Receivables topped out at $18682.0 in Q4 2010 and bottomed at $4671.0 in Q2 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2011 | 4,671.00 |
| Dec 31, 2010 | 18,682.00 |